



Abstract

Formulation and Characterization of a Methacrylated Chitosan Topical Treatment with Dispersed Magnetite Nanoparticles Functionalized with Hydrophobic Drugs Encapsulated in Liposomes †

Monica Gantiva-Díaz , Juan C. Cruz * and Carolina Muñoz-Camargo *

Department of Biomedical Engineering, Universidad de los Andes, Bogotá 111711, Colombia

* Correspondence: jc.cruz@uniandes.edu.co (J.C.C.); c.munoz2016@uniandes.edu.co (C.M.-C.)

† Presented at the 2nd International Electronic Conference on Biomolecules: Biomacromolecules and the Modern World Challenges, 1–15 November 2022; Available online: <https://iecbm2022.sciforum.net/>.

Abstract: Cutaneous administration has advantages over the oral or intravenous route, such as convenience for the patient, avoiding hepatic metabolism, and providing sustained administration of the active component over long periods of time. A major challenge in this route is the administration of drugs that are difficult to penetrate. For these, it is necessary to design delivery vehicles that help increase the stability of the active components and facilitate transport across the skin barrier. In this work, magnetoliposomes (MLPs) immobilizing magnetite nanoparticles (MNPs) have been realized. MNPs act as a nanocarrier for hydrophobic drugs, such as doxorubicin (DOX). To facilitate topical application, MLPs were dispersed in photoresponsive methacrylated chitosan hydrogels. For this purpose, the MLPs were synthesized by coprecipitation of FeCl_3 and FeCl_2 . Subsequently, they were silanized and functionalized by a PEG spacer to bind DOX. The success of each functionalization step was evaluated by Fourier transform infrared spectroscopy (FTIR) and thermogravimetric analysis (TGA). The size and morphology of the PEG-DOX-MNPs were analyzed by DLS and TEM. Then, the MNPs-PEG-DOX MNPs were encapsulated in liposomes synthesized by the layer hydration method. Dispersion of MLPs in the hydrogel, followed by crosslinking with visible blue light, was performed. Preliminary FTIR results indicate a correct synthesis and functionalization of the MNPs, as indicated by the presence of bands corresponding to the Si-O stretching vibration at 1029 cm^{-1} and Fe-O absorption bands around 560 cm^{-1} . TGA results showed a weight loss of 3.5% for MNPs from 200 to $400\text{ }^\circ\text{C}$, which was attributed to silane ligands. The hydrodynamic diameter of the MNPs was 140 nm with polydispersity indices of 0.16. In a future work, DOX will be conjugated to MNPs and MLPs will be synthesized for dispersion in the hydrogel. Subsequently, drug release kinetics tests will be performed under relevant conditions.



Citation: Gantiva-Díaz, M.; Cruz, J.C.; Muñoz-Camargo, C. Formulation and Characterization of a Methacrylated Chitosan Topical Treatment with Dispersed Magnetite Nanoparticles Functionalized with Hydrophobic Drugs Encapsulated in Liposomes. *Biol. Life Sci. Forum* **2022**, *20*, 27. <https://doi.org/10.3390/IECBM2022-13509>

Academic Editor: Vladimir Uversky

Published: 9 November 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Keywords: magnetoliposomes; nanoparticles; magnetite; skin drug delivery; ChiMa hydrogels

Supplementary Materials: The presentation material of this work is available online at <https://www.mdpi.com/article/10.3390/IECBM2022-13509/s1>.

Author Contributions: Conceptualization, J.C.C. and C.M.-C.; methodology, M.G.-D.; validation, M.G.-D.; formal analysis, M.G.-D.; investigation, M.G.-D.; resources, J.C.C. and C.M.-C.; data curation, M.G.-D.; writing—original draft preparation, M.G.-D.; writing—review and editing, M.G.-D., J.C.C. and C.M.-C.; visualization, M.G.-D.; supervision, J.C.C. and C.M.-C.; project administration, J.C.C. and C.M.-C.; funding acquisition, J.C.C. and C.M.-C. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the Colombian Ministry of Science, Technology, and Innovation (Minciencias), Grant IDs 782-2019 and 845-2018. Additional funding was provided by the 2019 Fundación Santafé de Bogotá-Uniandes grant “Production of recombinant antimicrobial peptides to modify materials of biomedical interest” and 2018 Fundación Santafé de Bogotá-Uniandes grant “Development of multifunctional magnetoliposomes as vehicles for the delivery of combined therapies of low dosage and high bioavailability for the treatment of parkinson’s disease”.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Acknowledgments: The authors thank the Department of Biomedical Engineering of the Universidad de los Andes for financial support and the Department of Biomedical Engineering and the Department of Chemical Engineering of the Universidad de los Andes for technical support.

Conflicts of Interest: The authors declare no conflict of interest.